About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in North Carolina | 15,496 Studies Near You | Clareo Health

Clinical Trials LocationsNorth Carolina

Clinical Trials in North Carolina

Discover 15,496 clinical trials near North Carolina. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 9061-9080 of 15,496 trials

COMPLETEDPhase 325 miles

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937

The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.

Papulopustular RosaceaErythematotelangiectatic Rosacea

bioRASI, LLC963 participantsStarted Feb 2015

Los Angeles, California, United States • San Diego, California, United States • Boca Raton, Florida, United States +24 more locations

COMPLETEDPhase 225 miles

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

NCT02785185

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.

Bausch Health Americas, Inc.150 participantsStarted Jun 2016

Rogers, Arkansas, United States • Beverly Hills, California, United States • Carlsbad, California, United States +10 more locations

Find Trials by Condition in North Carolina

Breast Cancerin North Carolina Lung Cancerin North Carolina Prostate Cancerin North Carolina Colorectal Cancerin North Carolina Melanomain North Carolina Leukemiain North Carolina Lymphomain North Carolina Pancreatic Cancerin North Carolina Ovarian Cancerin North Carolina Brain Cancerin North Carolina

Data from ClinicalTrials.govTerms

COMPLETEDPhase 338 miles

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

NCT03036124

The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

AstraZeneca4,744 participantsStarted Feb 2017

Fairhope, Alabama, United States • Mobile, Alabama, United States • Sheffield, Alabama, United States +416 more locations

COMPLETEDPhase 241 miles

A Clinical Trial of KT07 Capsule in the U.S.A

NCT02867358

The purpose of this study is to investigate clinical efficacy of KT07 capsule in alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza.

Influenza, Human

Yiling Pharmaceutical Inc.391 participantsStarted Sep 2016

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +78 more locations

COMPLETED41 miles

Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant

NCT03355235

The overall objectives in this study are to identify patterns of cognitive impairment pre- and post-transplant, to assess the similarities of scores of the three cognitive assessments in myeloma patients who undergo autologous stem cell transplant, and to determine if patients prefer the self-assessment, Self-Administered Gerocognitive Exam (SAGE) or the healthcare applied Montreal Cognitive Assessment (MoCA) assessment.

Stem Cell Transplant Complications

Wake Forest University Health Sciences50 participantsStarted Oct 2017

Winston-Salem, North Carolina, United States

COMPLETEDPhase 241 miles

Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin

NCT03211156

This is a randomized, double-blind, placebo-controlled Phase 2 study designed to determine if amoxicillin will eradicate vaginal colonization/infection with Gardnerella vaginalis (GV) when administered to women who are colonized/infected with GV but have no clinical evidence of Bacterial Vaginosis (BV). The study will be conducted at 2 clinics in the United States: University of Alabama at Birmingham and Wake Forest University Health Sciences. Entire study duration is approximately 24 months and subject participation duration is approximately 22 days. Approximately 245 healthy adult females, 18 to 45 years of age will be screened to enroll approximately 98 participants to achieve 82 evaluable participants at the test of cure (ToC) visit. Participants will be enrolled and randomized to one of two groups, either amoxicillin (2 x 250 mg capsules by mouth twice daily for 7 days) or placebo. Women who are enrolled will be asked to return for one further visit, Visit 2 (Day 15 - 21), where a ToC will be completed. For those not enrolled, participation will end at their post screening follow up phone call. Women will be asked to use condoms during their participation. The primary objective is to determine if treatment with amoxicillin eradicates GV in women who are colonized/infected with GV but have no clinical evidence of BV.

Vaginitis Gardnerella

National Institute of Allergy and Infectious Diseases (NIAID)97 participantsStarted Sep 2017

Birmingham, Alabama, United States • Winston-Salem, North Carolina, United States

COMPLETEDNA46 miles

Conventional Bite Wing Radiography Versus Stationary Intraoral Tomosynthesis, a Comparison Study

NCT02873585

A comparison of caries detection rates between conventional intraoral bitewing radiography and a stationary intraoral digital tomosynthesis (s-IOT) using a carbon nanotube X-ray source array. The secondary objective is to assess participants experience with the s-IOT device.

University of North Carolina, Chapel Hill32 participantsStarted Apr 2018

Chapel Hill, North Carolina, United States

COMPLETEDNA46 miles

A Study of the Feasibility of Prehospital Remote Ischemic Conditioning

NCT03400579

Prospective, single center, single arm pilot study evaluating the feasibility of delivering remote ischemic conditioning (RIC) by emergency medical services (EMS) in the prehospital setting. Eligible patients will have chest pain or anginal equivalent symptoms and require ground ambulance transport to the hospital. All subjects will undergo the standard RIC procedure (i.e., up to four cycles of alternating 5-min inflation and 5-min deflation) with the autoRIC® device (CellAegis Devices, Inc., Toronto, Ontario). The primary objective is to evaluate the number of cycles of RIC completed in patients having the procedure initiated by EMS in the prehospital setting.

University of North Carolina, Chapel Hill10 participantsStarted Jul 2018

Chapel Hill, North Carolina, United States

COMPLETEDPhase 257 miles

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

NCT02644668

This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal muscular atrophy (SMA).

Spinal Muscular Atrophy

Cytokinetics70 participantsStarted Jan 2016

Los Angeles, California, United States • Orange, California, United States • Palo Alto, California, United States +16 more locations

TERMINATEDPhase 365 miles

Study of Rapastinel as Monotherapy in Patients With MDD

NCT03560518

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).

Depressive Disorder, Major

Naurex, Inc, an affiliate of Allergan plc439 participantsStarted Jun 2018

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Anaheim, California, United States +37 more locations

COMPLETEDNA66 miles

Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD

NCT02634177

In this randomized clinical trial, subjects will be assigned to either an assay-guided treatment condition (AGT) or a treatment-as-usual condition (TAU). All subjects will provide a DNA sample at the Screening Visit for the Genecept Assay ™. In the AGT condition, assay results will be provided to the treating investigator, who will use the results to guide antidepressant pharmacotherapy. In the TAU condition, the investigator will treat the subjects without the knowledge of the pharmacogenetic testing results. Assay results for all subjects will be provided to the investigator once all Week 8 visit procedures have been completed. Raters of the primary endpoint assessment and subjects will remain blinded to treatment assignment.

Major Depressive Disorder

Genomind, LLC305 participantsStarted Jan 2016

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Springdale, Arkansas, United States +20 more locations

COMPLETEDPhase 2154 miles

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

NCT03482882

The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.

Treatment of Depression in Adults With Parkinson's Disease (PD)

ACADIA Pharmaceuticals Inc.47 participantsStarted Mar 2018

Costa Mesa, California, United States • Fountain Valley, California, United States • Pasadena, California, United States +18 more locations

COMPLETEDPhase 1186 miles

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

NCT01711515

This phase I trial studies the side effects and best dose of ipilimumab when given after chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as ipilimumab, may find tumor cells and help carry tumor-killing substances to them. Giving ipilimumab together with chemoradiation therapy may be a better way treat cervical cancer.

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise Specified+6 more

National Cancer Institute (NCI)34 participantsStarted Oct 2012

Los Angeles, California, United States • Los Angeles, California, United States • Orange, California, United States +13 more locations

COMPLETEDNA197 miles

Pancreas Resection With and Without Drains

NCT01441492

This randomized prospective trial is designed to test the hypothesis that pancreatectomy without routine intraperitoneal drainage does not increase the severity or frequency of complications within 60 days of surgery.

Pancreas TumorPancreatitis

Baylor College of Medicine399 participantsStarted Sep 2011

Gainesville, Florida, United States • Tampa, Florida, United States • Indianapolis, Indiana, United States +11 more locations

COMPLETEDPhase 3232 miles

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

NCT00948428

At the end of the study, safety and efficacy outcome measures will be compared to determine a) if dosing with Generic Imiquimod cream, 5% is therapeutically equivalent to the currently marketed Aldara (imiquimod) cream, 5% and b) if both imiquimod 5% creams are superior in comparison to the Vehicle cream.

Actinic Keratoses

Actavis Inc.462 participantsStarted May 2008

Hot Springs, Arkansas, United States • Fresno, California, United States • San Diego, California, United States +17 more locations

COMPLETEDPhase 2291 miles

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

NCT02680002

The main purpose of this study is to assess the usability of long-term stored H5N1 antigen and adjuvant. The study is designed to assist in stockpile management by assessing the safety, reactogenicity, and immunogenicity long-term stored influenza A/Vietnam/H5N1 vaccine when administered with or without MF59® adjuvant.

A/Vietnam/H5N1 Influenza Virus

Biomedical Advanced Research and Development Authority422 participantsStarted Mar 2016

Atlanta, Georgia, United States • Council Bluffs, Iowa, United States • Lenexa, Kansas, United States +3 more locations

TERMINATEDPhase 2293 miles

AMG 827 in Subjects With Psoriatic Arthritis

NCT01516957

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

Psoriatic Arthritis

Bausch Health Americas, Inc.168 participantsStarted Oct 2011

Peoria, Arizona, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +28 more locations

TERMINATEDPhase 1392 miles

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

NCT03597282

The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma. The study will also investigate an alternative schedule for the administration of the NEO-PV-01 vaccine. Study interventions will be assessed by both clinical and immune responses to treatment.

Metastatic Melanoma

BioNTech US Inc.22 participantsStarted Oct 2018

Scottsdale, Arizona, United States • Los Angeles, California, United States • Denver, Colorado, United States +5 more locations

COMPLETEDPhase 1472 miles

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

NCT02343536

The goal of the study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP. To evaluate the safety and maximum tolerated dose (MTD) or the maximal administered dose (MAD) of CC-486 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with high risk (IPI 2 or more) previously untreated DLBCL or Grade 3B FL. Also, to determine pharmacokinetics (PK) of CC-486 when administered alone and in combination with R-CHOP and to explore preliminary efficacy of CC-486 plus R-CHOP by 2007 International Working Group (IWG) criteria.

Lymphoma, Large B-Cell, DiffuseLymphoma, Follicular

Celgene59 participantsStarted Apr 2015

Tampa, Florida, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +4 more locations

COMPLETEDPhase 3709 miles

An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

NCT00799266

This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids

Novartis Pharmaceuticals34 participantsStarted Dec 2008

Westmead, New South Wales, Australia • Vancouver, British Columbia, Canada • Winnipeg, Manitoba, Canada +9 more locations

PreviousPage 454 of 775Next

Diabetes

in North Carolina

Heart Diseasein North Carolina